LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 97

Search options

  1. Article ; Online: Epidemiology and causes of cardiogenic shock.

    Berg, David D / Bohula, Erin A / Morrow, David A

    Current opinion in critical care

    2021  Volume 27, Issue 4, Page(s) 401–408

    Abstract: Purpose of review: Cardiogenic shock is a complex clinical syndrome of end-organ hypoperfusion due to impaired cardiac performance. Although cardiogenic shock has traditionally been viewed as a monolithic disorder predominantly caused by severe left ... ...

    Abstract Purpose of review: Cardiogenic shock is a complex clinical syndrome of end-organ hypoperfusion due to impaired cardiac performance. Although cardiogenic shock has traditionally been viewed as a monolithic disorder predominantly caused by severe left ventricular dysfunction complicating acute myocardial infarction (AMI), there is increasing recognition of the diverse causes of cardiogenic shock and wide spectrum of clinical severity. The purpose of this review is to describe the contemporary epidemiology of cardiogenic shock, including trends in clinical outcomes and recent efforts to refine risk assessment.
    Recent findings: The incidence of cardiogenic shock among patients with AMI has remained remarkably stable at 3-10%; however, the proportion of cardiogenic shock cases related to AMI has decreased over time to ∼30%, while the proportion of cardiogenic shock cases due to acute decompensated heart failure has steadily increased. Estimated in-hospital mortality from cardiogenic shock in contemporary registries is approximately 30-40%, suggesting modest improvement in cardiogenic shock outcomes over the last decade. There is a wide spectrum of clinical severity among patients presenting with cardiogenic shock, which is described by the Society for Cardiovascular Angiography and Interventions clinical staging criteria.
    Summary: Improved clinical characterization and risk assessment of patients with cardiogenic shock may facilitate more effective clinical investigations of this morbid clinical syndrome.
    MeSH term(s) Heart Failure ; Hospital Mortality ; Humans ; Myocardial Infarction ; Registries ; Shock, Cardiogenic/epidemiology ; Shock, Cardiogenic/etiology
    Language English
    Publishing date 2021-06-03
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 1235629-3
    ISSN 1531-7072 ; 1070-5295
    ISSN (online) 1531-7072
    ISSN 1070-5295
    DOI 10.1097/MCC.0000000000000845
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: The Nexus of Heart Failure and Critical Care Cardiology.

    Sinha, Shashank S / Bohula, Erin A / Katz, Jason N

    Journal of cardiac failure

    2021  Volume 27, Issue 10, Page(s) 1041

    MeSH term(s) Cardiology ; Critical Care ; Heart Failure/diagnosis ; Heart Failure/therapy ; Humans
    Language English
    Publishing date 2021-10-08
    Publishing country United States
    Document type Editorial
    ZDB-ID 1281194-4
    ISSN 1532-8414 ; 1071-9164
    ISSN (online) 1532-8414
    ISSN 1071-9164
    DOI 10.1016/j.cardfail.2021.09.004
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Multi-marker risk assessment in patients hospitalized with COVID-19: Results from the American Heart Association COVID-19 Cardiovascular Disease Registry.

    Bhatt, Ankeet S / Daniels, Lori B / de Lemos, James / Goodrich, Erica / Bohula, Erin A / Morrow, David A

    American heart journal

    2023  Volume 258, Page(s) 149–156

    Abstract: Background: The pathobiology of inflammation, thrombosis, and myocardial injury associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) may be assessed by circulating biomarkers. However, their relative prognostic importance has been ...

    Abstract Background: The pathobiology of inflammation, thrombosis, and myocardial injury associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) may be assessed by circulating biomarkers. However, their relative prognostic importance has been incompletely described.
    Methods: We analyzed data from patients hospitalized with COVID-19 from January 2020, to April 2021, at 122 US hospitals in the American Heart Association (AHA) COVID-19 cardiovascular (CV) disease registry. Patients with data for D-dimer, C-reactive protein (CRP), ferritin, natriuretic peptides [NP], or cardiac troponin (cTn) at admission were included. cTn quintiles were indexed to the assay-specific 99th percentile reference limits. Using multivariable logistic regression, we assessed the association between each biomarker by quintile [Q] and odds of in-hospital death and a cardiovascular and thrombotic composite outcome.
    Results: Of 32,636 registry patients, 26,424 (81%) had admission values for ≥1 of the key biomarkers, of which 4,527 (17%) had admission values for all 5 biomarkers. Each biomarker revealed a significant gradient for in-hospital mortality from Q1 to Q5: D-dimer 14% to 35%, CRP 11%-32%, ferritin 11% to 30%, cTn 13% to 43%, and NPs 7% to 35% (P
    Conclusions: Among patients hospitalized with COVID-19, cTn and NPs identified patients at high risk for an in-hospital adverse cardiovascular outcome, while elevations in D-dimer identified patients at risk for thrombotic complications.
    MeSH term(s) Humans ; COVID-19/complications ; Cardiovascular Diseases/epidemiology ; SARS-CoV-2 ; Hospital Mortality ; American Heart Association ; RNA, Viral ; Biomarkers ; C-Reactive Protein ; Risk Assessment ; Registries ; Ferritins
    Chemical Substances RNA, Viral ; Biomarkers ; C-Reactive Protein (9007-41-4) ; Ferritins (9007-73-2)
    Language English
    Publishing date 2023-01-18
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 80026-0
    ISSN 1097-6744 ; 0002-8703
    ISSN (online) 1097-6744
    ISSN 0002-8703
    DOI 10.1016/j.ahj.2022.12.014
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Resource use among patients with transcatheter cardiac valve procedures admitted to contemporary cardiac intensive care units: insights from CCCTN.

    Bhatt, Ankeet S / Berg, David D / Palazzolo, Michael G / Alviar, Carlos L / Bohula, Erin A / Morrow, David A

    European heart journal. Acute cardiovascular care

    2023  Volume 13, Issue 2, Page(s) 245–246

    MeSH term(s) Humans ; Intensive Care Units ; Hospitalization ; Cardiac Surgical Procedures ; Heart Valves ; Aortic Valve Stenosis ; Treatment Outcome
    Language English
    Publishing date 2023-10-04
    Publishing country England
    Document type Journal Article
    ZDB-ID 2663340-1
    ISSN 2048-8734 ; 2048-8726
    ISSN (online) 2048-8734
    ISSN 2048-8726
    DOI 10.1093/ehjacc/zuad118
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Response to Mei et al. regarding the incidence and predictors of hospitalization for heart failure among patients with stable atherosclerosis in the TRA 2°P-TIMI 50 trial.

    Freedman, Benjamin L / Berg, David D / Scirica, Benjamin M / Bohula, Erin A / Goodrich, Erica L / Sabatine, Marc S / Morrow, David A / Bonaca, Marc P

    Clinical cardiology

    2023  Volume 46, Issue 3, Page(s) 348–349

    MeSH term(s) Humans ; Incidence ; Atherosclerosis/epidemiology ; Myocardial Infarction/epidemiology ; Heart Failure/diagnosis ; Heart Failure/epidemiology ; Heart Failure/therapy ; Hospitalization
    Language English
    Publishing date 2023-01-24
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 391935-3
    ISSN 1932-8737 ; 0160-9289
    ISSN (online) 1932-8737
    ISSN 0160-9289
    DOI 10.1002/clc.23972
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Pulmonary Artery Diastolic Pressure as a Surrogate for Pulmonary Capillary Wedge Pressure in Cardiogenic Shock.

    Papolos, Alexander I / Kenigsberg, Benjamin B / Singam, Narayana Sarma V / Berg, David D / Guo, Jianping / Bohula, Erin A / Katz, Jason N / Diepen, Sean VAN / Morrow, David A

    Journal of cardiac failure

    2024  

    Abstract: Background: It is common for clinicians to use the pulmonary artery diastolic pressure (PADP) as a surrogate for the pulmonary capillary wedge pressure (PCWP). Here, we determine the validity of this relationship in patients with various phenotypes of ... ...

    Abstract Background: It is common for clinicians to use the pulmonary artery diastolic pressure (PADP) as a surrogate for the pulmonary capillary wedge pressure (PCWP). Here, we determine the validity of this relationship in patients with various phenotypes of cardiogenic shock (CS).
    Methods and results: In this analysis of the Critical Care Cardiology Trials Network registry, we identified 1225 people admitted with CS who received pulmonary artery catheters. Linear regression, Bland-Altman and receiver operator characteristic analyses were performed to determine the strength of the association between PADP and PCWP in patients with left-, right-, biventricular, and other non-myocardia phenotypes of CS (eg, arrhythmia, valvular stenosis, tamponade). There was a moderately strong correlation between PADP and PCWP in the total population (r = 0.64, n = 1225) and in each CS phenotype, except for right ventricular CS, for which the correlation was weak (r = 0.43, n = 71). Additionally, we found that a PADP ≥ 24 mmHg can be used to infer a PCWP ≥ 18 mmHg with ≥ 90% confidence in all but the right ventricular CS phenotype.
    Conclusions: This analysis validates the practice of using PADP as a surrogate for PCWP in most patients with CS; however, it should generally be avoided in cases of right ventricular-predominant CS.
    Language English
    Publishing date 2024-03-19
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1281194-4
    ISSN 1532-8414 ; 1071-9164
    ISSN (online) 1532-8414
    ISSN 1071-9164
    DOI 10.1016/j.cardfail.2024.02.021
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Management of Non-ST-Elevation Myocardial Infarction: The Bright Gleam of Progress, but Much Work Remains.

    Bohula, Erin A / Antman, Elliott M

    JAMA

    2016  Volume 316, Issue 10, Page(s) 1045–1047

    MeSH term(s) Disease Management ; Electrocardiography ; Humans ; Myocardial Infarction ; Non-ST Elevated Myocardial Infarction
    Language English
    Publishing date 2016-09-13
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 2958-0
    ISSN 1538-3598 ; 0254-9077 ; 0002-9955 ; 0098-7484
    ISSN (online) 1538-3598
    ISSN 0254-9077 ; 0002-9955 ; 0098-7484
    DOI 10.1001/jama.2016.11940
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Lorcaserin Safety in Overweight or Obese Patients.

    Bohula, Erin A / Wiviott, Stephen D / Scirica, Benjamin M

    The New England journal of medicine

    2018  Volume 380, Issue 1, Page(s) 100

    MeSH term(s) Benzazepines ; Humans ; Obesity ; Overweight
    Chemical Substances Benzazepines ; lorcaserin (637E494O0Z)
    Language English
    Publishing date 2018-12-29
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMc1813971
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Epidemiology of heart failure hospitalization in patients with stable atherothrombotic disease: Insights from the TRA 2°P-TIMI 50 trial.

    Freedman, Benjamin L / Berg, David D / Scirica, Benjamin M / Bohula, Erin A / Goodrich, Erica L / Sabatine, Marc S / Morrow, David A / Bonaca, Marc P

    Clinical cardiology

    2022  Volume 45, Issue 8, Page(s) 831–838

    Abstract: Background: Heart failure (HF) is a growing public health problem and ischemic heart disease is an important risk factor. Understanding the epidemiology of HF in patients with atherosclerosis may help identify subgroups at greater risk who have the ... ...

    Abstract Background: Heart failure (HF) is a growing public health problem and ischemic heart disease is an important risk factor. Understanding the epidemiology of HF in patients with atherosclerosis may help identify subgroups at greater risk who have the potential to derive greater benefit from preventive strategies.
    Methods and results: The TRA 2°P-TIMI 50 trial randomized 26,449 patients with stable atherosclerosis to the antiplatelet agent vorapaxar versus placebo. Hospitalization for HF (HHF) endpoints were adjudicated from serious adverse events by blinded structured review using established definitions. HHF incidence was estimated using Kaplan-Meier analysis. Independent predictors of HHF risk were identified using multivariable logistic regression. The effect of vorapaxar on HHF risk was explored using Cox regression. The estimated incidence of HHF at 3 years was 1.6%. Independent predictors of HHF included prior HF (adjusted odds ratio [adj-OR]: 8.31; 95% confidence interval [CI]: 6.56-10.54), age (adj-OR [per 10 years]: 1.67; 95% CI: 1.47-1.89), type 2 diabetes mellitus (T2DM; adj-OR: 2.55; 95% CI: 2.01-3.24), polyvascular disease (two-territory disease, adj-OR: 1.89; 95% CI: 1.46-2.44; three-territory disease, adj-OR: 2.68; 95% CI: 1.94-3.70), chronic kidney disease (CKD; adj-OR: 1.65; 95% CI: 1.30-2.11), body mass index (BMI; adj-OR [per 5 kg/m
    Conclusions: In patients with stable atherosclerosis, prior HF, age, T2DM, polyvascular disease, CKD, BMI, prior MI, and hypertension are important predictors of HHF risk.
    MeSH term(s) Atherosclerosis/epidemiology ; Child ; Child, Preschool ; Diabetes Mellitus, Type 2/drug therapy ; Heart Failure/diagnosis ; Heart Failure/drug therapy ; Heart Failure/epidemiology ; Hospitalization ; Humans ; Hypertension ; Myocardial Infarction/epidemiology ; Renal Insufficiency, Chronic ; Risk Factors ; Treatment Outcome
    Language English
    Publishing date 2022-07-19
    Publishing country United States
    Document type Journal Article ; Randomized Controlled Trial
    ZDB-ID 391935-3
    ISSN 1932-8737 ; 0160-9289
    ISSN (online) 1932-8737
    ISSN 0160-9289
    DOI 10.1002/clc.23843
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Efficacy and Safety of Non-Vitamin-K Antagonist Oral Anticoagulants Versus Warfarin Across the Spectrum of Body Mass Index and Body Weight: An Individual Patient Data Meta-Analysis of 4 Randomized Clinical Trials of Patients With Atrial Fibrillation.

    Patel, Siddharth M / Braunwald, Eugene / Steffel, Jan / Boriani, Giuseppe / Palazzolo, Michael G / Antman, Elliott M / Bohula, Erin A / Carnicelli, Anthony P / Connolly, Stuart J / Eikelboom, John W / Gencer, Baris / Granger, Christopher B / Morrow, David A / Patel, Manesh R / Wallentin, Lars / Ruff, Christian T / Giugliano, Robert P

    Circulation

    2024  Volume 149, Issue 12, Page(s) 932–943

    Abstract: Background: The efficacy and safety of non-vitamin-K antagonist oral anticoagulants (NOACs) across the spectrum of body mass index (BMI) and body weight (BW) remain uncertain.: Methods: We analyzed data from COMBINE AF (A Collaboration Between ... ...

    Abstract Background: The efficacy and safety of non-vitamin-K antagonist oral anticoagulants (NOACs) across the spectrum of body mass index (BMI) and body weight (BW) remain uncertain.
    Methods: We analyzed data from COMBINE AF (A Collaboration Between Multiple Institutions to Better Investigate Non-Vitamin K Antagonist Oral Anticoagulant Use in Atrial Fibrillation), which pooled patient-level data from the 4 pivotal randomized trials of NOAC versus warfarin in patients with atrial fibrillation. The primary efficacy and safety outcomes were stroke or systemic embolic events (stroke/SEE) and major bleeding, respectively; secondary outcomes were ischemic stroke/SEE, intracranial hemorrhage, death, and the net clinical outcome (stroke/SEE, major bleeding, or death). Each outcome was examined across BMI and BW. Because few patients had a BMI <18.5 kg/m
    Results: Among 58 464 patients, the median BMI was 28.3 (interquartile range, 25.2-32.2) kg/m
    Conclusions: The treatment effect of NOACs versus warfarin in atrial fibrillation is generally consistent for stroke/SEE across the spectrum of BMI and BW, whereas the reduction in major bleeding is attenuated in those with higher BMI or BW. Death and the net clinical outcome are overall reduced with NOACs over warfarin, although there remain uncertainties for these outcomes at a very high BMI and BW.
    MeSH term(s) Humans ; Warfarin/adverse effects ; Anticoagulants/adverse effects ; Atrial Fibrillation/diagnosis ; Atrial Fibrillation/drug therapy ; Atrial Fibrillation/chemically induced ; Body Mass Index ; Administration, Oral ; Randomized Controlled Trials as Topic ; Hemorrhage/complications ; Stroke/epidemiology ; Stroke/etiology ; Stroke/prevention & control ; Body Weight ; Treatment Outcome
    Chemical Substances Warfarin (5Q7ZVV76EI) ; Anticoagulants
    Language English
    Publishing date 2024-01-24
    Publishing country United States
    Document type Meta-Analysis ; Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 80099-5
    ISSN 1524-4539 ; 0009-7322 ; 0069-4193 ; 0065-8499
    ISSN (online) 1524-4539
    ISSN 0009-7322 ; 0069-4193 ; 0065-8499
    DOI 10.1161/CIRCULATIONAHA.123.066279
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top